Sanofi
Julia Schwendner, Process Responsible Scientist, smiling in a green lab coat, hairnet and safety goggles while standing in front of industrial bioprocessing equipment at Sanofi's Frankfurt facility.

Julia Schwendner, Process Responsible Scientist, Frankfurt, Germany

Julia Schwendner, Process Responsible Scientist, Frankfurt, Germany

Third Quarter 2025

Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community.


Our Latest Stories

Aurora Loh, a biotechnologist in protective gear, inspecting large-scale machinery at Sanofi Modulus Singapore.

Our Science

October 8, 2025

Modulus: Redefining the Future of Biopharma Manufacturing

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

About Us

Who We Are

We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.

Our Pipeline

5

Therapeutic areas

93

Compounds in clinical development

26

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases


October 24, 2025
Press release: Q3: continued sales and earnings progress

October 22, 2025
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

October 20, 2025
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program

October 20, 2025
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors